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1. Introduction  
It is reported that oxidative stress plays an important part in the pathogenesis of 
cardiovascular diseases in chronic kidney disease (CKD) patients. This contributes to the 
increased cardiovascular morbidity and mortality in that group of patients. Clinical studies 
point to links between oxidative stress, inflammation, anemia and malnutrition (Panichi et 
al., 2011). The presence of inflammation and the length of duration of dialysis are the most 
important determinants of oxidative stress, which make them additional risk factors of 
cardiovascular disease. There are several deficiencies of antioxidant defense mechanisms 
which have been found in CKD patients. These include reduced levels of vitamin C, 
increased levels of oxidized vitamin C, reduced intracellular levels of vitamin E, reduced 
selenium concentrations, and deficiency in the glutathione scavenging system (Locatelli et 
al., 2003). 
The main interest of this chapter is particularly focused on the effect of vitamin C infusion 
and vitamin E-coated membrane on hemodialysis-induced oxidative stress and, also setting 
this issue in the broader context of oxidative stress mitigation and the search for appropriate 
markers of oxidative stress. 
The level of oxidative stress can be determined by several markers, because oxidants 
themselves have very short half-lives. Only lipids, proteins, carbohydrates, and nucleic acids 
modified by oxy-radicals are suitable as markers because of their long lifetime. According to 
the NKF KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients 
these markers include lipid peroxidation products (such as malonyldialdehyde (MDA), 
exhaled alkanes, oxidized low-density lipoproteins, advanced lipid oxidation products), 
oxidatively modified arachidonic acid derivatives (such as F2-isoprostanes and 
isolevuglandins); oxidatively modified carbohydrates (such as reactive aldehydes and 
reducing sugars); oxidatively modified aminoacids (such as cysteine/cystine, 
homocysteine/homocystine, 3-chlorotyrosine, 3-nitrotyrosine); oxidatively modified 
proteins (such as thiol oxidation, carbonyl formation, advanced oxidation protein products, 
3-nitrotyrosine, advanced glycation end-products and oxidatively modified DNA (such as  
8 hydroxy 2’deoxyguanine) (K/DOQI Workgroup, 2005). In the literature other oxidative 
stress markers are also mentioned, such as the lipid peroxidation products acrolein,  
4-hydroxynonenal or thiobarbituric acid-reactive substances (TBARS); evaluation of 
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enzymatic anti-oxidant systems (erythrocyte content of SOD (superoxide dismutase) and 
GSH (glutathione), plasma levels of GSHPx (glutathione peroxidase)), non-enzymatic anti-
oxidants (plasma levels of vitamin C, erythrocyte content of GSH and vitamin E) and 
inflammatory proteins (C-reactive protein (CRP), albumin) (Locatelli et al., 2003). With such 
a broad range of suitable markers of oxidative stress available, prioritizing them becomes 
difficult.  
Several steps have been taken to minimize oxidative stress in CKD patients. They include:  
1. supplementation of vitamin E 
A daily supplement of 400–800 IU of vitamin E is recommended for secondary prevention of 
cardiovascular events and for prevention of recurrent muscle cramps (Fouque et al., 2007). 
In a double blind randomized trial, 60 hemodialysis patients divided into four groups 
received either vitamin E (400 mg), vitamin C (250 mg), both vitamins or a placebo daily for 
8 weeks (Khajehdehi et al., 2001). Muscle cramps significantly declined in patients receiving 
both vitamins E and C (97%), vitamin E alone (54%), or vitamin C (61%) as compared with 
only 7% of placebo-treated patients (Khajehdehi et al., 2001). The SPACE trial tested the 
effect of vitamin E (800 IU/day) on a combined cardiovascular endpoint in 196 
hemodialized patients with pre-existing cardiovascular disease, and showed a significant 
benefit from vitamin E supplementation (Boaz et al., 2003). However, the HOPE study 
showed no survival benefit of vitamin E in patients with mild to moderate CKD (Mann et 
al., 2004). 
2. supplementation of vitamin C  
Current recommendations for maintenance of hemodialysis patients advise 
supplementation with ascorbic acid 75-90 mg daily (Fouque et al., 2007) during dialysis. In 
addition to the potential benefits of vitamin C for anemia management, the importance of 
adequate vitamin C with regard to improving cardiovascular outcomes in hemodialysis 
patients is also the subject of research. A study by Deicher and colleagues of 138 incident 
hemodialysis patients examined baseline levels of plasma vitamin C and followed the cohort 
for occurrence of cardiovascular events (Deicher et al., 2005). Results showed that low total 
vitamin C plasma concentrations (less than 32 μmol/L) were associated with an almost 
fourfold increased risk for fatal and major nonfatal cardiovascular events compared with 
hemodialysis patients who had higher plasma vitamin C levels (greater than 60 μmol/L). 
On the other hand Nankivell and Murali reported oxalosis resulting in graft failure in  
a kidney transplant recipient who had been taking self-prescribed doses of vitamin C 2,000 
mg daily as a dialysis patient for the three years prior to the transplant (Nankivell & Murali, 
2008). Similarly, a case report by McHugh and colleagues (McHugh et al., 2008) describes 
mortality from vitamin C-induced acute renal failure. Vitamin C supplements appear to 
improve functional iron deficiency and hence the response to erythropoietin (EPO) (Keven 
at el., 2003). Vitamin C supplementation may help to relieve muscle cramps. In a double 
blind randomized trial the supplementation of vitamin C improved muscle cramps in 61% 
of patients as compared with only 7% of placebo-treated patients (Khajehdehi et al., 2001). In 
the study performed by Tarng DC. et al. vitamin C supplementation in chronic 
hemodialized patients resulted in the reduction of lymphocyte 8-OHdG levels and the 
production of intracellular reactive oxygen species (Tarng et al., 2004). 
3. combination of vitamin C and E supplementation 
In a double blind randomized trial the combination of vitamin C and E supplementation 
improved muscle cramps significantly in 97% of patients as compared with only 7% of 
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placebo-treated patients (Khajehdehi et al., 2001). In the Kuopio Atherosclerosis Prevention 
Study (KAPS) the supplementation of these two vitamins slowed the progression of carotid 
artery lesions (Salonen et al., 1995). 
4. supplementation of acetylcysteine 
In the randomized, controlled trial (Tepel et al., 2003) the antioxidant supplementation was 
associated with a reduced number of cardiovascular events in patients undergoing 
hemodialysis. 
5. proper management of anemia 
The literature is ambiguous with regard to anemia management. Red blood cells contain  
a high level of antioxidants. In their research, Siems W. et al. indicated that a rise in the red 
blood cell count may increase total antioxidative capacity (Siems et al., 2002). However, 
Drueke T. et al. in their study concluded that the intravenous injection of iron may induce 
an increase in protein oxidation and carotid atherosclerosis (Drueke et al., 2002). 
6. modified type of dialysis membrane 
7. high-flux hemodialysis 
Ward RA. et al. showed the association between the use of high-flux hemodialysis and an 
improvement in some measures of protein oxidation (Ward et al., 2003). There is also 
evidence of reduced levels of cytokines such as IL-6 and C-reactive protein and a positive 
effect on oxidative stress of high-flux hemodialysis in comparison with conventional 
hemodialysis (Panichi, 2006). 
2. Dialysis membranes 
2.1 Modified type of dialysis membrane – the vitamin E-coated dialyser 
The very first human hemodialysis therapy made use of a cellulose-based material with 
collodion tube membranes (Haas, 1888). Cellophane and Cuprophan membranes replaced 
collodion tube membranes later, due to their better performance In the 1960s regenerated 
cellulose was established as the principal membrane material. Dialysis with unmodified 
cellulose membranes is associated with such bioincompatibility phenomena as leukopenia, 
increased expression of adhesion molecules on leukocytes, and release of reactive oxygen 
species. Modifications in the structure of the hydroxyl groups in cellulose membranes led to 
the development of another type of membrane material, modified cellulose, with improved 
bioincompatibility. These modifications include replacement of the hydroxyl groups with 
other chemical structures, such as acetyl derivatives, or their bonding with different 
compounds, such as vitamin E or heparin.  
Vitamin E, which is well-known for being a lipophilic antioxidant of cell membranes and 
lipoproteins (Traber & Atkinson, 2007), was introduced to the field of hemodialysis for the 
first time in the late 1990s to produce a cellulose-based vitamin E-modified dialyser (on the 
market as Excebrane dialyser, Asahi Kasei Medical Co., Ltd, Tokyo, Japan). It was used as  
a modifier (or coating agent) for the blood surface of cellulosic hollow-fiber dialyser 
membranes. In the last few years, studies have reported the positive effect of vitamin  
E-coated membranes on surrogate markers of oxidative stress and inflammation in 
hemodialysis patients (Cruz et al., 2008). Satoh M. et al. proved that vitamin E-modified 
cellulose dialysis membranes have a beneficial effect on reduction of oxidative stress (Satoh 
et al., 2001). Miyazaki H. et al. also found good results for endothelial dysfunction (Miyazaki 
et al., 2000).  
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Study Study design 
Sample  
size 
Study 
duration 
[months] 
Age 
(mean, 
range) 
Males  
(%) 
Mean duration 
of dialysis 
(mean) [years] 
Buoncristiani  
1997 
Single arm 10 1,0 67 40 4,9 • 
Sommerburg  
1999 
Single arm 10 1,5 51 70 NR • 
Mune  
1999 
RCT 25 24,0 57 44 7,0 • 
Bonnefont-
Rousselot  
2000 
Single arm (cross 
over with 
conventional 
hemodialysis) 
12 3,0 50 67 1,5  
• 
• 
Galli  
2001 
RCT 15 
One single 
HD session or 
after 3 months 
64 50 2,6  
• 
• 
Eiselt  
2001 
RCT (cross over 
with conventional 
hemodialysis) 
10 
1 month or 3 
month 
63 NR 3,6  
• 
• 
Mydlik  
2001 
Single arm 8 0,8 54 38 NR 
• 
Shimazu  
2001 
RCT 6 9,0 59 50 11,2 
• 
Satoh  
2001 
Single arm 18 6,0 68 55 >3,0 
• 
Tsuruoka  
2002 
Randomized 
crossover 
10 10,0 55 NR 9,5 
• 
Usberti  
2002 
Single arm 10 7,0 22–75a 55 1,5–17,0a 
• 
Triolo  
2003 
Single arm 10 12,0 65  60 7,2 
• 
Hara  
2004 
Single arm 13 12,0 62  31 13,1 
• 
Mydlik  
2004 
Single arm 14 3,0 43  50 NR 
• 
w
w
w
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Only one systematic review conducted by Sosa MA. et al. provided comprehensive data that 
the transfer of dialysis patients to a vitamin E-coated dialyser is associated with an 
improvement in circulating biomarkers of lipid peroxidation, which is of potential clinical 
benefit (Sosa et al., 2006). Fourteen articles were included: 11 single arm, one randomized 
crossover and two randomized controlled trials, with a total of 37 to 158 evaluable patients. 
Metanalyses were conducted for malondialdehyde (MDA), thiobarbituric acid reactive 
substances (TBARS), combination of MDA and TBARS, low-density lipoprotein (LDL) and 
oxidized-LDL. There were three studies from Europe with analysis of data for TBARS1 – 
Eiselt 2001, Galli 2001 and Bonnefont-Rousselot 2000. All three studies had an arm where  
E-coated membranes were used (single arm cross over design - Galli 2001 and Bonnefont-
Rousselot 2000, randomized controlled trial – Eiselt 2001) with a total of 37 patients. Mean 
patient ages ranged from 44 to 65 years with mean durations of dialysis ranging from 3 
months to 2,6 years. The studies lasted from 1 to 3 months.  
In this systematic review, all results were metanalysed, which seems not to be 
methodologically correct. The summary estimate of all of the three studies revealed a non-
significant decrease in pre-dialysis TBARS level of -0,4 mmol/L (CI95% -1,2; 0,4). In  
a sensitivity analysis excluding the study by Galli 2001, the overall mean decrease in pre-
dialysis TBARS level was similar (-0.6 mmol/L, CI95% -1,4; 0,2), and expressed extremely 
low baseline values. Bonnefont-Rousselot 2000 had a younger group of patients, a shorter 
duration of dialysis, and in addition, high flux dialysis was used. Additionally, the results of 
all three trials were presented for 3 different periods – after one session – Eiselt 2001, after 1 
month – Galli 2001 and after 3 months - Bonnefont-Rousselot 2000.  
 
Study Unit and parameter Excebrane Control P value Assessment 
Bonnefont-
Rousselot  
2000 
µmol/L 
Median (range) 
1,72 
(1,02-3,0) 
1,65
(0,75 -
2,25) 
ns 
Pre-dialysis level 
and after 3 months 
of HD 
Eiselt  
2001 
µmol/L 
Mean ± SEM 
3,9 ± 0,15 
4,09 ± 
0,14 
ns 
Pre-dialysis level 
and after single 
session of HD 
Galli  
2001 
nmol/l - measured by 
HPLC and espressed 
as malonaldehyde 
equivalents 
Mean ± SD 
4,8 ± 2,4 
12,9 ± 
5,2 
<0,001 
Excebrane 
hemodialysis in 
comparison with 
CLS hemodialysis 
after 1 month 
HD, hemodilaysis; HPLC, high performance liquid chromatography; SD, standard deviation; ns, not 
statistically significant. 
Table 2. Thiobarbituric acid reacting substances (TBARS) – mode of measure, units and p 
value results in Sosa 2006. 
The overall conclusion from the systematic review (Sosa 2006) based on the MDA and 
TBARS results was presented as the standardized effect size. The mean decrease in these 
biomarkers of lipid peroxidation (from 13 studies) was statistically significant at -1.7 units 
(CI95%, -2.7, -0.7).  
                                                 
1 This is only one possibile biomarker to compare Excebrane with the results of data from trials 
regarding the efficacy of vitamin C infusion and vitamin E-coated membrane hemodialysis.  
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2.2 Vitamin C infusion and E-coated membrane hemodialysis 
In order to assess the influence of vitamin C infusion and E-coated membrane hemodialysis 
a systematic review was conducted. The primary sources used to identify clinical studies 
included a literature search in PubMed (last search on 11th March in 2011) limited to clinical 
trials on humans using the searched terms ‘dialysis’, ‘hemodialysis’, ‘renal replacement 
therapy’, ‘membrane’, ‘vitamin E’, ‘vitamin C’ and ‘infusion’, and a literature search in the 
Cochrane Central Register of Controlled Trials, using the same searched terms without 
period limitations. Additionally, study references from relevant articles were reviewed and 
the relevant articles themselves. Non-English language studies were excluded. All primary 
studies meeting the following criteria concerning study population, interventions and 
reference interventions and study types were included: study population - patients with 
chronic renal failure (or renal transplantation), hemodialysis. Both patients with and 
without history of cardiovascular disease were included. Interventions and comparators: 
vitamin C alone or combined with defined dosage and vitamin E-coated dialysers for 
hemodialysis patients. Acceptable reference technologies include either placebos or  
a dialyser without vitamin E coating, with biocompatibility similar to the vitamin E-coated 
dialyser. We searched the data published as randomized controlled clinical trials. No 
restrictions were placed on minimal study duration or sample size. The inclusion and 
exclusion criteria defined above were used to pre-select articles by screening titles and 
abstracts primarily thematically, and a full text version of articles that might meet the 
inclusion criteria was ordered. Two independent reviewers (T.M. and M.W.)2 evaluated the 
abstracts for relevance to the study topic. The data were extracted if they examined the 
impact on changes in circulating pre-dialysis biomarkers of lipid peroxidation, including 
malondialdehyde (MDA), thiobarbituric acid reactive substances (TBARS) and other 
parameters. The laboratory methods used to determine the levels of these biomarkers were 
also evaluated. The initial literature search returned 118 citations from PubMed, 368 
citations from the Cochrane database. A total of 44 citations met the initial screening criteria 
and were retrieved and evaluated. Out of those, 40 studies were excluded for the following 
reasons: 5 studies examined the effect of oral vitamin E and vitamin C supplementation, 13 
studies examined only the effect of vitamin C supplementation with or without additional 
substances (oral or infusions in comparison with placebo), 14 studies focused on the 
biocompatibility of the Excebrane dialyser or other E-coated membrane dialyser, 3 citations 
were review articles, editorials or case reports, 1 study documented changes exclusively in 
pre-dialysis hemoglobin level and/or recombinant human erythropoietin (rHuEpo) dosing 
requirement, 1 study measured biomarkers of oxidative stress in vitro, 3 studies compared  
a different type of membrane without vitamin C infusion. Finally, 3 studies (2 fully 
published trials (Yang 2006, Eiselt 2001) and 1 conference abstract (Racek 1999) met the 
review criteria and examined the effect of the vitamin C infusion and E-coated membrane 
hemodialysis on biomarkers of oxidative stress. In these two trials patients were 
randomized to groups with or without vitamin E-coated membrane dialyser and with or 
without vitamin C infusion. The overall duration of individual studies ranged from one 
dialysis session to 12 weeks. Duration of dialysis ranged from 3 to 153 months (no data for 
Yang 2006). Male gender distribution ranged from 50 to 70%. Mean age is about 65 (no data 
for Yang 2006). Causes of end-stage renal disease were documented in 2 trials.  
  
 
                                                 
2 M.W. – Magdalena Wladysiuk, T.M. – Teresa Malecka-Massalska 
www.intechopen.com
  
N
R
, n
o
t rep
o
rted
; A
O
S
, an
tio
x
id
an
t cap
acity
; G
S
H
, g
lu
tath
io
n
e; G
S
H
O
x
, g
lu
tath
io
n
e p
ero
x
id
ase; S
O
D
, 
su
p
ero
x
id
e d
ism
u
tase; M
D
A
, m
alo
n
d
iald
eh
y
d
e; V
C
, v
itam
in
 C
; R
H
2O
2, referen
ce H
2O
2; R
O
S
, reactiv
e 
o
x
y
g
en
 sp
ecies; T
A
S
, to
tal an
tio
x
id
an
t statu
s; T
B
A
R
S
, th
io
b
arb
itu
ric acid
 reactin
g
 su
b
stan
ces; m
etH
b
, 
m
eth
em
o
g
lo
b
in
; P
C
O
O
H
, p
h
o
sp
h
atid
y
lch
o
lin
e h
y
d
ro
p
ero
x
id
e. 
T
ab
le 3. T
h
e ch
aracteristics o
f th
e in
d
iv
id
u
al stu
d
ies an
d
 o
u
tco
m
e m
easu
res in
 th
e p
resen
t 
sy
stem
atic rev
iew
. 
Author 
and  
year 
Country 
Study 
design 
Study 
duration 
Sample size 
Age  
(mean, range) 
Males 
(%) 
Mean 
duration of 
dialysis 
(mean, range) 
[months] 
Eiselt 
2001A 
Czech Republic 
Randomized 
controlled 
trial 
Single 
dialysis 
session 
(before/ 
after) 
24 
(4 groups 
with 6 
persons) 
66 
(41-85) 
58 
41 
(8-153) 
Eiselt 
2001B 
Czech Republic 
Randomized 
controlled 
trial 
12 weeks 
20 
(2 groups – 
10 patients) 
64 
(37-79) 
50 
32 
(3-84) 
●TBARS 
●AOC in
●GSH in 
●SOD in 
●G
Yang 
 2006 
Taiwan 
Randomized 
controlled 
trial 
8 weeks 
80 
(4 groups for 
20 patients) 
NR 69 NR 
●Pla
●Blood ROS reactive oxygen species counts
●RH2O2 
●Vitamin C, Vi
●Total antioxidant status T
●Pla
●metHb le
●PCOOH, 
●C-reactive protein (CRP)
Racek 
1999 
Czech Republic NR NR 24 NR LD NR 
●MDA leve
●VC leve
●GSH in 
●SOD in 
●G
w
w
w
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Author  
and year 
Type of intervention in group - membrane 
type (dialyser name) 
Vitamin C infusion dosage 
Eiselt  
2001A 
Protocol O – CL C15NL cellulose dialyser 
(Terumo Corp., Tokyo, Japan) 
Protocol OC - CL C15NL and vitamin C 
infusion  
Protocol E - CL E15NL dialyser (vitamin 
E-modified cellulose membrane Excebrane, 
Terumo Corp.)  
Protocol EC - CL E15NL dialyser 
(Excebrane) with vitamin C infusion  
Vitamin C (acidum 
ascorbicum, Biotika, Czech 
Republic) in 20 ml of saline 
before the blood entered the 
dialyser. The infusion rate 
was  
2.1 mg/min - 504 mg per 
dialysis.  
Eiselt  
2001B 
1 group - HD with vitamin C during 
dialysis  
2 group – HD without any treatment  
 
The CL C15NL membrane was used for the 
first 4 weeks, to be followed by the E 
membrane (4 weeks), and again CL C15NL 
for the last 4 weeks of the study.  
Yang  
2006 
1 group - HD with vitamin C infusion  
2 group - HD with VE-coated dialyser  
3 group - HD with VE-coated dialyser and 
vitamin C infusion 
4 group - HD with neither 
 
1 and 4 group - PSN (Polysynthane 
membrane, Baxter Healthcare Co., 
Deerfield, IL, USA)  
2 and 3 group – VE-coated - EE18 
Excebrane (Terumo Co., Shibuyaku, Japan)  
1 g of ascorbic acid in 250 ml 
of saline infused over 4 h of 
HD 
Racek  
1999 
No data about the division patients to 
groups - CL C15NL cellulose dialyser 
(Terumo) conventional or E-modified 
membrane – with or without vitamin C 
infusion 
500 mg of ascorbic acid 
infused over 4 h of HD 
HD, hemodialysis; PA, polyamide; CU, cuprophane; CTA, cellulose triacetate; CL, Clirans series; NR, 
not reported.  
Table 4. Type of interventions in group, membrane type (dialyser name) and vitamin C 
dosage in the present systematic review. 
Eiselt 2001 presented the data for TBARS level in the short- and long-term observational 
period. After single session no change in the plasma levels of TBARS was observed after the 
dialysis with vitamin E-coated membrane with or without vitamin C infusion. In single 
session dialysis a rise from the baseline was only significant at the end of dialysis in the 
group with a nonmodified membrane (Protocol O - without vitamin C infusion). 
www.intechopen.com
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TBARS level 
in plasma 
before HD after HD  
µmmol/L Mean SEM Mean SEM P value 
O 3,95 0,11 4,26 0,11 p<0,002 
OC 4,28 0,15 4,18 0,15 Ns 
E 3,90 0,15 4,09 0,14 Ns 
EC 4,05 0,16 4,06 0,15 Ns 
HD, hemodialysis; O, cellulose membrane; OC, cellulose membrane and vitamin C infusion; E, vitamin 
E-modified membrane; EC, vitamin E-modified membrane and vitamin C infusion, ns – non statistical 
significance   
Table 5. Thiobarbituric acid reacting substances (TBARS) in plasma before and after 
hemodialysis (HD) in the short-term period in Eiselt 2001. 
For long-term data on predialysis TBARS levels were comparable in two groups with and 
without vitamin C infusion. A significant decrease in TBARS, regardless of whether or not 
vitamin C was infused, was demonstrated in the results with the vitamin E-coated 
membrane after 4 weeks of nonmodified dialysis. Additionally, there was  
a significant difference in the group with vitamin E-coated membrane and vitamin C 
infusion also with baseline (p<0,02). TBARS returned to baseline in both groups after 
switching patients to a nonmodified membrane. In Eiselt 2001 no changes over time or 
differences between the study groups were noted with the intracellular antioxidants 
glutathione, superoxide dismutase, and glutathione peroxidase.  
 
Parameter and units 
Eiselt 2001 
E-coated membrane 
E-coated membrane and 
vitamin C infusion 
Mean and range Before After Before After 
GSH  
(mmol/L 
erythrocyte) 
Single 
session 
1,40 
(1,11–1,9) 
1,42 
(1,01–1,96) 
1,39 
(1,07–2,13) 
1,46 
(1,01–1,77) 
1 month
1,82 
(1,13–2,05) 
1,66 
(1,31–1,90) 
1,71 
(1,41–2,02) 
1,62 
(1,36–2,41) 
SOD  
(IU/g Hb) 
Single 
session 
908 
(603–1 217) 
920 
(595–1 394) 
958 
(677–1 235) 
930 
(623–1 239) 
1 month
1 014 
(893–1 284) 
946 
(873–1,469) 
1 040 
(854–1 269) 
972 
(771–1 383) 
GSHPx  
(IU/g Hb) 
Single 
session 
40,2 
(29,0–54,9) 
38,8 
(29,5–63,1) 
36,9 
(26,2–61,3) 
37,0 
(28,2–61,1) 
1 month
33,1 
(21,8–73,7) 
33,65 
(21,7–72,1) 
40,6 
(19,8–51,9) 
44,6 
(25,2–51,3) 
Table 6. Glutathione (GSH) and superoxide dismutase (SOD) in erythrocytes and 
glutathione peroxidase (GSHPx) in blood in the short-term and long-term study in Eiselt 
2001. 
In Racek 1999 conventional dialysis without vitamin C infusion was only significantly 
connected with increasing MDA level (from 3,8 0,5 to 4,2 0,6 µmol/l). Switching to vitamin 
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E-coated membrane did not increase the level of MDA neither with or without vitamine C 
infusion. The intracellular antioxidants glutathione, superoxide dismutase, and glutathione 
peroxidase during the study did not change in any of the group.  
2.3 Vitamin E-coated polysulfone membrane  
Lately, in its search for biocompatible biomaterials, hemodialysis technology has introduced 
a vitamin E-coated dialyser using polysulfonemembranes to the market (VitabranE ViE, 
Asahi Kasei Kuraray Medical Co., Tokyo, Japan). A significant reduction in plasma  
C-reactive protein in hemodialysis has been observed with the vitamin E-coated dialyser 
using polysulfonemembranes (Cruz et al., 2008). A reduced need for erythropoietin-
stimulating agents (ESAs) has also been reported with a vitamin E-coated dialyser using 
polysulfonemembranes. This may be due to the longer red blood cell survival resulting from 
reduced oxidative stress and inflammation (Cruz et al., 2008). This new vitamin E-coated 
polysulfone membrane has been demonstrated to have a redox capacity and to actively react 
with redox-active substances in the blood (Floridi et al., 2009). It has also been reported that 
the vitamin E-coated polysulfone membrane combines the antioxidant and antithrombotic 
activities of α-tocopherol with the biocompatibility of polysulfone membranes, which have 
excellent clearance and permeability properties (Sasaki, 2006). Evidence show that vitamin 
E-coated polysulfone membrane plays a great role in the management of uremic anemia. 
However, there is a limited number of preliminary studies on that area. For example, one 
preliminary study published as a pilot study states a positive effect of vitamin E-bonded 
membranes on anemia in hypo-responder dialysis patients (Andrulli et al., 2010). Another 
study shows new positive effects of vitamin E-coated membranes on blood pressure level in 
dialysed patients (Matsamura et al., 2010). Recently, there are findings that these 
membranes may play an effective role in the management of uremic anemia and lead to  
a reduction in the chronic low-grade inflammatory response of patients with uremic 
syndrome (Panichi et al., 2011). 
3. Discussion  
In patients with CKD, markers of oxidative modification of lipids (Handelman et al., 2001; 
Oberg et al. 2004) and proteins (Nguyen-Khoa et al., 2001) are present at high levels. 
Moreover, various markers of oxidative stress seem to be associated with higher mortality 
and cardiovascular disease in dialysis patients (Bayes et al., 2005; Descamps-Latscha et al., 
2005). When talking about the oxidative stress among hemodialyzed patients, there is  
a question that should be taken into great consideration; that is, what are the most 
appropriate biomarkers in relation to the disease state. The relevant biomarkers can be 
divided into three groups: enzymatic (superoxide dismutase, catalase, glutathione 
peroxidase), non-enzymatic (gluthatione, vitamin E, vitamin C, ferritin, transferrin, 
albumin) and the third group of lipids, proteins, carbohydrates and nucleic acids modified 
by oxy-radicals. None of these groups seem to be perfect for assessment of oxidative stress 
levels. The markers from the enzymatic group have a half-life of seconds, which makes their 
determination in vivo infeasible (Locatelli et al., 2003). The level of markers from the second 
group may vary a lot due to malnutrition, anemia and inflammation among hemodialyzed 
patients, common problems in that group of patients. The markers from the third group 
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have lifetimes from hours to weeks. From the diagnostic point of view this makes them 
ideal, but their large number makes it difficult to prioritize any one as the most ideal for the 
hemodialyzed patient group. Giustarini et al. describes the characteristic of the “ideal 
marker” (see Table 7; Giustarini, et al., 2009). Upon reviewing these characteristics, it 
becomes clear that finding “the ideal and the most reliable one” for that group of patients 
would be almost impossible. 
 
No Characteristic of biomarker 
1 Chemically stable molecule 
2 Directly implicated in the onset and/or progression of disease 
3  Specific for the reactive oxygen/nitrogen species in question 
4  Non-invasive assessment 
5  Low intra- and inter-variability in humans 
6 
accurate, precise, specific, sensitive, interference-free, and validated assays for 
quantitative analysis 
7  Consensus and establishment of reference intervals and values 
8  Consensus and establishment of animal models 
 
Table 7. Characteristics of and requirements for suitable biomarkers of oxidative stress 
(Giustarini, et al., 2009). 
A review of the literature offers examples of how different markers were used to examine 
the oxidative stress among patients with end-stage renal disease. This makes it difficult to 
compare research on the same subject, because studies that measure the same process with 
different, nonstandardized markers. Here are examples: 8-hydroxy 2’-deoxyguanosine  
(8-OHdG) is known as a product of DNA damage (Tarng et al., 2000) and a novel marker for 
the assessment of oxidative DNA damage in reactive oxygen species-mediated diseases 
(Kasai, 1997). Zocalli et al. found asymmetric dimethyloarginine (ADMA) to be a strong and 
independent predictor of overall mortality and cardiovascular outcome in hemodialysis 
patients (Zocalli et al., 2001). In the study of Kamgar et al., the panel of following markers of 
oxidative stress were used: plasma protein carbonyl, F-2 isoprostane, C-reactive protein and 
plasma IL-6 (Kamgar et. al., 2009). Interestingly, the authors of this paper came to the 
conclusion that the addition of a potent antioxidant cocktail to conventional vitamin 
supplements had no effect on the severity of end-stage renal disease-induced oxidative 
stress, inflammation, hypertension, anemia or nutritional disorders in hemodialysis patients 
(Kamgar et al., 2009). There are some studies where TBARS were used as markers of 
oxidative stress (Ramos et al., 2008; Galli et al., 2001) whereas others made use of advanced 
glycation end products (AGEs), free pentosidine (FP), protein-bound pentosidine (BP), 
autoantibodies against oxidized LDL (ox-LDL-autoantibodies (Baragetti et al., 2006), and 
MDA (Giardini et al., 1984). The table below summarizes different biomarkers of oxidative 
stress used among hemodialyzed patients (Giustarini, et al., 2009). The table was created on 
the basis of studies of human subjects published on PubMed between January and June 2006 
(Giustarini, et al., 2009). This indicates how many biomarkers have been used to assess 
oxidative stress; these studies used different methods and took samples from different 
tissues. 
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 Precursor Bio marker Method Tissue Healthy Disease Reference 
1 CRF  MDA  TBA  
spectrophotometry 
Plasma 6,20 nmol/L  11,9  Ece  
et al., 2006 
2 HD  MDA  TBA  
spectrophotometry 
Plasma 2,29 μmol/L  4,36  Zwolinska  
et al., 2006 
3 CRF  15-F2t-IsoP  ELISA commercial kit, 
Assay Design  
Plasma 84,3 pg/mL  
 
328  Cottone  
et al., 2006 
4 HD  PCO  Fluoresceinamine  
spectrophotometry  
Plasma 2,06 nmol/mg 
protein  
2,51  
 
Mera  
et al., 2005 
5 HD  SOD  ELISA commercial kit, 
BenderMedSystm  
Plasma 58,6 ng/mL  305  Pawlak  
et al., 2006 
6 HD GPx  EIA commer 
cial kit, Byoxy tech  
Plasma 116 U/L  N.A.  Huerta  
et al., 2006 
7 HD  
 
Ab anti oxi-
LDL  
ELISA commer 
cial kit, Bio medica 
Plasma 210 mU/ 
mL  
380  Pawlak  
et al., 2006 
8 HD  Oxi-LDL  ELISA anti-oxidized 
phosphate dylcholine  
Plasma 0,2 ng/μg 
LDL protein  
1,8  Sasaki,  
2006 
9 HD  4-HNE  HPLC UV/vis detection  Plasma 3,0 μmol/mg 
protein  
7,6  Odetti  
et al., 2006 
10 HD  AGE  fluorescence  
 
Plasma 232 
fluorescece  
intensity 
746  Mera  
et al., 2005 
11 HD  HMA  HPLC fluorescence 
detection  
Plasma 55,7%  45,3  
 
Mera  
et al., 2005 
12 HD  HNA1  HPLC fluorescence 
detection  
Plasma 36,5%  44,8  
 
Mera  
et al., 2005 
13 HD  HNA2  HPLC fluorescence 
detection  
Plasma 7,8%  9,3  
 
Mera  
et al., 2005 
14 HD  Organic  
hydro 
peroxides  
Ferrous oxidation xylenol 
orange assay 
spectrophotometry  
Plasma 0,65 μmol/L  
 
1,99  Zwolinska  
et al., 2006 
15 CRF  GSH  Acid deprote 
inization/DTNB 
spectrophotometry  
Whole 
blood 
1684 μmol/L  938  Ece  
et al., 2006 
16 CRF  SOD  NTB/riboflavin 
spectrophotometry  
Red blood 
cells 
3457 U/gHb  2072  Ece  
et al., 2006 
17 HD  SOD  Epinephrine  
spectrophotometry  
Red blood 
cells 
1750 U/g Hb  1240  Zwolinska  
et al., 2006 
18 HD  Gpx  NADPH/ 
GSH spectrophotometry  
Red blood 
cells 
83,2 U/gHb  38,4  
 
Zwolinska  
et al., 2006 
19 CRF  Catalase  H2O2  
spectrophotometry  
Red blood 
cells 
1705 k/gHb  1212  Ece  
et al., 2006 
20 HD  Catalase  H2O2  
spectrophotometry  
Red blood 
cells 
0,49 U/gHb  0,36  Zwolinska  
et al., 2006 
21 CRF  GSH  Acid deproteinization/ 
DTNB  
spectrophotometry  
Red blood 
cells 
14,2 
μmol/gHb  
 
20,5  Stepniewska  
et al., 2006 
22 HD  MDA  TBA  
spectrophotometry  
Red blood 
cells 
5,86 μmol/L  11,34  Zwolinska  
et al., 2006 
23 CRF  GR  GSSG/ 
NADPH  
spectrophotometry  
Red blood 
cells 
1,95 U/gHb  2,57  Stepniewska  
et al., 2006 
24 CRF  G6PDH  NADP  
spectrophotometry  
Red blood 
cells 
2,54 U/gHb  4,91  Stepniewska  
et al., 2006 
 
Table 8. Summary of different biomarkers of oxidative stress used among hemodialyzed 
patients on the basis of studies of human subjects published between January and June 2006 
(Giustarini, et al., 2009). 
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AGEs, advanced glycation end-products; CRF, chronic renal failure; DTNB, 5,5’-dithiobis-(2-
nitrobenzoic acid); EIA, enzyme immunoassay; G6PDH, glucose-6 phosphate 
dehydrogenase; GPx, glutathione peroxidase; GSH, glutathione; GSSG, glutathione 
disulfide; GR, glutathione reductase; HD, hemodialysis; HMA, albumin reduced; HNA1, 
mixed disulfide between albumin an low molecular mass thiols; HNA2, SH groups in 
albumin oxidized to sulfenic, sulfinic, sulfonic acid; HPLC, high-performance liquid 
chromatography; 4-HNE, 4-hydroxy-2-Nonenal; MDA, malondialdehyde; N.A., not 
applicable; oxi-LDL- oxidized low molecular lipoproteins; NBT, nitroblue tetrazolium; PCO, 
protein carbonyls; SOD, superoxide dismutase; TBA, thiobarbituric acid; TBARS, 
thiobarbituric acid-reactive substances. (Giustarini, et al., 2009) 
In the systematic review conducted in 2006 (Schnell-Inderst 2006) only two studies analyzed 
the clinical endpoints of cardiovascular disease, results that are meaningful to patients. Due 
to the absence of clinically-meaningful endpoints, the relevance of studies analyzing the 
effect of anti-oxidative vitamins on intermediate endpoints like oxidative stress markers is 
fundamentally limited. In 17 studies with intermediate endpoints, supplementation with 
vitamins was associated with a change of one or several of the examined endpoints in the 
expected direction, such as a decrease in concentrations of biomarkers for oxidative stress, 
an improvement of the lipid profile, a reduced progression of aortic calcification or decrease 
of intimate media thickness. Due to the methodological quality of studies (heterogeneity of 
population, lack of standardization for interventions, and others) and contradictory results, 
the statement that anti-oxidative vitamins can play any role in secondary prevention for 
cardiovascular disease among patients with end-stage renal disease is neither supported nor 
rejected. Additionally, there is no relevant data for primary prevention of cardiovascular 
disease. 
In the present systematic review the main objectives was to find any evidence that vitamin C 
infusion added to the vitamin E-coated membrane dialyser could change the level of 
biomarkers. The Sosa 2006 systematic review and the results for Excebrane should be  
a reference’s level to assess the effect of additional C infusion. Varying conclusions for the 
TBARS outcome drawn by individual studies in Sosa maybe due to methodological 
differences. The cross over design of the same group of patients with small and insufficient 
sample size, different baseline risk of patients (comorbidity, time of dialysis) and, especially, 
the lack of parallel randomized control did not allow for the control of confounders (Sosa 
2006). Additionally, a lack of standardized measurement of biomarkers and the time of 
measurement (single session, 1 month or longer) of biomarker assays probably does not 
allow any metanalyses to be performed. In this case only a qualitative systematic review 
could be made with separate conclusions for each of the subpopulations or patient groups. 
Single-arm groups (from observational or randomized trials) were metanalyzed as  
a measure of baseline level and then change over the time proposed by the authors of 
included studies. Natural fluctuations of biomarkers and their changes over time due to 
other interventions (comorbidities, diet, stress, age) could bias the results. There are existing 
head–to-head trials of Excebrane directly with other dialysers which could provide more 
reliable data. The same problems with population, interventions and measured outcomes 
were raised by the present systematic review. Additionally, the number of biomarkers and 
the lack of an answer to the question of which of them is the most ideal indicator of 
oxidative stress prevents us from coming to the final conclusion regarding the effect of 
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vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative 
stress. 
For our systemic review, TBARS was used as oxidative stress marker in order to compare 
the effect of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced 
oxidative stress. TBARS and MDA are recommended by the National Kidney Foundation 
(NKF) guidelines to assess oxidative stress; however, they are not perfect measures of 
oxidative stress. MDA is a product of lipid peroxidation. During that process there are other 
end-products such as pentane, isoprostanes, and conjugated dienes (Esterbauer, 1993). The 
TBARS determination is the most-used assay to assess lipid peroxidation. In this assay, 
thiobarbituric acid (TBA) reacts with aldehydes to produce a relatively stable chromophore 
that can be quantified using either spectrophotometry or high-performance liquid 
chromatography (HPLC) (Pompella et al., 1997). What is worth noting is that there are 
several problems with the use of TBARS in human fluids. Griffiths et al. underlines that 
aldehydes other than MDA may react with TBA to produce derivatives that absorb light in 
the same wavelength range; degradation of fatty acids can occur during the analysis, 
leading to false information about the actual MDA content in the fluid before testing 
(Griffiths et al., 2002). Halliwell and Chirico add that the presence of metal ions can increase 
the rate of this decomposition, whereas metal-chelating molecules can decrease this rate, 
making reliability a problem. What is more, the routine use of different anticoagulants to 
prevent blood clotting, i.e.,EDTA or heparin, may yield different values even on the same 
blood sample, and most TBA-reactive materialin human body fluids, including MDA, is not 
a specific product of lipid peroxidation and may produce false-positive results (Halliwell & 
Chirico, 1993). These problems led some researchers to use an HPLC modification of the 
TBARS method. This approach uses HPLC to separate the MDA-TBA adduct from 
interfering chromophores, thereby resulting in improved specificity (Halliwell & Chirico, 
1993). Lipid hydroperoxides and aldehydes can also be absorbed from the diet and excreted 
in urine. It follows that measurements of MDA in plasma or urine can be confounded by 
diet and should not be used as an index of whole-body lipid peroxidation unless diet is 
strictly controlled (Wilson et al., 2002). This illustrates the difficulty in assessing which 
method is the best for assessment of oxidative stress. Moreover, it also underlines the need 
for analytical methodologies which validate the stability of the biomarker and extraction 
yield, accuracy and precision, selectivity and specificity, robustness and limits of detection 
and quantitation (Shah et al., 2000). 
Currently, there is no consensus regarding an ideal marker of oxidative stress. So far,  
a panel of markers might be a better solution than just one (Locatelli et al., 2003). In order to 
analyze the process of oxidative stress there is no doubt that biomarkers should firstly be 
adequately validated, as too many have been proposed and used. Only under these 
circumstances can adequate conclusions be drawn and compared.  
4. Conclusion  
The available evidence is not sufficient to support an additional effect of the anti-oxidative 
role (measured by TBARS level) of a vitamin C infusion added to E-coated membrane 
dialyser in comparison to the vitamin E-coated dialyser alone. Methodological differences 
among three studies which used TBARS as a biomarker of oxidative stress prevent any 
www.intechopen.com
A Systematic Review of the Effect of Vitamin C Infusion and  
Vitamin E-Coated Membrane on Hemodialysis-Induced Oxidative Stress 
 
115 
significant conclusion regarding this supplementation from being made. These results 
together with the systematic review of Sosa 2006 have limited importance in light of the lack 
of evidence that measurement of some biomarkers can give conclusive results regarding 
oxidative stress in cardiovascular morbidity of dialysis patients. 
Finally, finding the most appropriate single biomarker or the most appropriate panel of 
biomarkers of oxidative stress in dialysis patients should be the first and most crucial step 
taken in order to decrease methodological uncertainty in future research on the issue.  
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